The United Kingdom and the United States have reached a major bilateral deal that will maintain zero tariffs on UK drug products entering the American market.
The Terms of the Deal
As part of the deal, the UK has pledged to raise spending on pharmaceuticals through the public health system. This pledge ensures that import taxes on these vital products will stay at zero for a duration of 36 months.
This deal follows recent threats to dramatically increase tariffs on patented pharmaceutical imports, with figures mentioned as high as 100%.
"This agreement between the United Kingdom bolsters the worldwide climate for cutting-edge drugs and introduces long-overdue fairness to American-British medicine commerce," a statement said.
Economic Significance
Pharmaceuticals represent one of the the United Kingdom's most significant goods shipped to the America, which is by far the largest destination for major UK drugmakers.
Export figures reveal that in the year leading up to last September, the UK exported pharmaceutical products totaling billions to the US. This value accounted for nearly one-fifth of British export trade in that span.
"This deal secures work, stimulates investment and sets the stage for the UK to emerge as a international leader for life sciences," a minister remarked.
Key UK Commitments
The deal includes several key changes from the British government:
- Price Threshold Increase: The UK will raise the cost ceiling at which it judges new treatments to be too expensive by 25%.
- Increased NHS Spending: There is a target to increase total NHS spending on drugs from 0.3 percent of Gross Domestic Product to 0.6% over the coming ten years.
- Rebate Cap: The sum pharmaceutical firms must pay back to the NHS to stay within budget will be restricted at fifteen percent. In the past, rebates exceeded twenty percent.
Industry Background
The deal comes amid a long-running row between the drug companies and the UK government over medicine costs and approval rates.
The disagreement were heightened by claims that US consumers were charged several times more for the equivalent treatments than consumers in the Britain and the EU.
Recently, several major manufacturing plans in the UK have been halted or abandoned, while major investments have been pledged toward American operations.
A senior figure acknowledged that the NHS needed to increase expenditure on medicines, noting that its expenditure on drugs had shrunk as a proportion of its overall budget over the previous ten-year period.
